Clinical Trial Update: Efficacy of 30-day Duration of Fidaxomicin for Recurrent C. Difficile Infection [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating 30-day fidaxomicin duration for recurrent Clostridium difficile infection; study terminated with posted results in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridium Difficile Infection

Drugs mentioned

• Fidaxomicin (fidaxomicin)

Snippet

Sponsor: McMaster University | Conditions: Clostridium Difficile Infection | Phase 3 | Status: TERMINATED | Results posted: 2023-03-24